Walden Biosciences
PrivateLast Round
Series A
Oct 6, 2020
Total Funding Raised
$51M
Company Overview
Walden Biosciences operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in October 2020.
Walden Biosciences is a biotechnology company that develops targeted therapies for kidney diseases, including chronic kidney disease and acute kidney injury.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Walden Biosciences Comparables
Compare Walden Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| River 3 Renal Corp. | 86% | |
| Purespring Therapeutics | 77% | |
| Dimerix Ltd | 76% |
For institutional investors. Book with your work email.
Walden Biosciences Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Walden Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCB Ventures | Series A |
| UCB Ventures | Series A |
| ARCH Venture Partners | Series A |
| ATEM Capital | Series A |
| Pandect Bioventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 28, 2025
Howard Mayer, M.D. appointed to the Board of Directors.
For institutional investors. Book with your work email.
Walden Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Walden Biosciences's valuation, stock price, and market status.
Is Walden Biosciences a public or private company?
Walden Biosciences is a private company.
What is the current stock price of Walden Biosciences?
Walden Biosciences is a private company, so its shares have no public market price. Caplight tracks Walden Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Walden Biosciences worth (valuation)?
Valuation information for Walden Biosciences is not publicly available.
Can I buy Walden Biosciences stock?
Walden Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Walden Biosciences's last funding round?
Walden Biosciences's most recent funding round was Series A on October 6, 2020.
Who are the main investors in Walden Biosciences?
Key investors in Walden Biosciences include UCB Ventures, UCB Ventures, ARCH Venture Partners.
Will Walden Biosciences IPO soon?
No public IPO plans have been announced for Walden Biosciences.
How can I track Walden Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Walden Biosciences's shares on secondary markets.